Acceleron Pharma Inc. (XLRN) — Financial statements
Income statement, balance sheet, and cash flow for Acceleron Pharma Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 93↑25.0% | 74↑428.9% | 14↑3.8% | 13↓51.5% | 28 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 93↑25.0% | 74↑428.9% | 14↑3.8% | 13↓51.5% | 28 | |
| Operating Expenses | ||||||
| R&D Expenses | 174↑13.0% | 154↑48.2% | 104↑15.8% | 90↑30.8% | 69 | |
| General & Administrative Expenses | 0.00 | 0.00↓100.0% | 35↑2.3% | 34↑33.4% | 25 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 0.00 | 0.00↓100.0% | 35↑2.3% | 34↑33.4% | 25 | |
| Other Expenses | 86↑52.1% | 56 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 260↑23.5% | 210↑52.0% | 138↑12.1% | 123↑31.5% | 94 | |
| Total Costs & Expenses | 260↑23.5% | 210↑52.0% | 138↑12.1% | 123↑31.5% | 94 | |
| Operating Results | ||||||
| Operating Income | -167↓22.6% | -136↓9.7% | -124↓13.1% | -110↓66.4% | -66 | |
| Depreciation & Amortization | 4↓2.4% | 4↑5.2% | 4↑32.6% | 3↑68.6% | 2 | |
| EBITDA | -163↓35.1% | -121↓5.1% | -115↓9.0% | -106↓90.9% | -55 | |
| EBIT | -167 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest & Other Income | ||||||
| Net Interest Income | 3↓73.2% | 11↑92.3% | 6↑118.1% | 3↑37.7% | 2 | |
| Interest Income | 3↓73.2% | 11↑92.3% | 6↑118.1% | 3↑37.7% | 2 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 1↓88.7% | 12↑108.9% | 6↑253.4% | 2↓82.9% | 9 | |
| Income Before Tax | -166↓32.9% | -125↓5.1% | -119↓9.7% | -108↓90.2% | -57 | |
| Income Tax Expense | 0.02↑133.9% | -0.06↓129.6% | -0.03↓184.4% | 0.03↑33.3% | 0.02 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -166↓33.0% | -125↓5.0% | -119↓9.6% | -108↓90.2% | -57 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -166↓33.0% | -125↓5.0% | -119↓9.6% | -108↓90.2% | -57 | |
| Bottom-Line Net Income | -166↓33.0% | -125↓5.0% | -119↓9.6% | -108↓90.2% | -57 | |
| EPS (Basic) | -2.92↓22.7% | -2.38↑8.1% | -2.59↑3.4% | -2.68↓76.3% | -1.52 | |
| EPS (Diluted) | -2.92↓22.7% | -2.38↑8.1% | -2.59↑3.4% | -2.68↓76.3% | -1.52 | |
| Weighted Average Shares | 57↑8.3% | 52↑14.3% | 46↑13.6% | 40↑8.0% | 37 | |
| Weighted Average Diluted Shares | 57↑8.3% | 52↑14.3% | 46↑13.6% | 40↑8.0% | 37 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.